When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Table 2 Timeline of the control, quality of life and perspective of the patient, with the inflammatory and the lung function values

	ACT	ACQ	AQLQ	FeNO (ppb)	IgE ( kU/l)	Blood eosinophils (mm³)	Sputum eosinophils (%)	Exacerbations previous 12 months	FEV₁ Pre-bronch (%)	FEV₁ Post-bronch (%)
First visit at asthma clinic	8	4.29	3.07	86	1510	239	8	9	67	73
Two weeks after exacerbation treated by OCS	17	1.43	5.27	45		443	46		64	92
INITIATION Mepolizumab
6-month evaluation Mepolizumab	21	1.71	5.53	96		81.83	16.8	2	82	89
18-month evaluation Mepolizumab	17	1.86	5.27	116		20	4	3	67	85
30-month evaluation Mepolizumab	16	2.86	4.47	157	2190	60	14	0	55	79
42-month evaluation Mepolizumab	17	2.43	4.8	119	4390	47	3.6	0	59	83
STOP mepolizumab and INITIATION dupilumab
Dupilumab 6-month evaluation	17	2.14	5.2	32	1184	930	38	0	59	83
18-month evaluation Dupilumab	17	1.43	5.67	46	337	700	24	0	79	85
30-month evaluation Dupilumab	21	1.57	5.6	44	283	410	5	0	86	95

ISSN: 1752-1947